Riskpilot← Back to searchSign inGet full accessATB Antivirals Oy
OYActiveY-tunnus 3199181-2Tykistokätu 4Manufacture of pharmaceutical preparations · NACE 2120Est. 20212 employeeswww.atbantivirals.com
Revenue 2025
EUR 0
EBITDA margin
—
+75% vs 2024
Equity ratio
-25.0%
Financial strength
Net profit 2025
EUR -123K
+19% vs 2024
| Revenue | EUR 0 | — |
| EBITDA | EUR -11K | +75% |
| Net profit | EUR -123K | +19% |
| Total assets | EUR 309K | -22% |
| Equity | EUR -77K | -343% |
| Employees | 2 | — |
Legal name
ATB Antivirals Oy
Y-tunnus number
3199181-2
Legal form
Osakeyhtiö
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
19. maaliskuuta 2021
Share capital
EUR 4 840
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala: Lääkkeiden ja muiden lääkevalmisteiden valmistus, markkinointi ja myynti (21200). Ihonhoitotuotteiden, virusten torjuntaan käytettävien tuotteiden sekä lääkkeiden valmistus, markkinointi ja myynti. Arvopaperikauppa sekä muu laillinen liiketoiminta.
Address
Tykistokätu 4
Phone
+3580413640948
Email
preethy.paul@atbantivirals.com
Website
www.atbantivirals.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −25 | −72 | −27 | −27 | −0 |
| EBITDA | −40 | −102 | 0 | −43 | −11 |
| Depreciation & amort. | — | −43 | −80 | −104 | −108 |
| EBIT | −40 | −145 | 0 | −147 | −119 |
| Net financials | −0 | 0 | 0 | −5 | −4 |
| Profit before tax | −40 | −145 | 0 | −152 | −123 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −40 | −145 | 0 | −152 | −123 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 372 | 550 | 543 | 395 | 309 |
| Equity | 363 | 218 | 82 | 32 | −77 |
| Long-term debt | — | 326 | 460 | 358 | 358 |
| Short-term debt | 9 | 6 | 1 | 5 | 28 |
| Total debt | 9 | 332 | 461 | 363 | 387 |
EBITDA margin
-1078500.0%
This company
15.8%
Market median
-6826049% vs market
20212025
Equity ratio
-25.0%
This company
38.2%
Market median
-165% vs market
20212025
Return on equity
-12251700.0%
This company
18.4%
Market median
-66585426% vs market
20212025
Net profit margin
-12251700.0%
This company
8.1%
Market median
-151255656% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
5.00×
This company
0.62×
Market median
-706% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PP Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (3) | ||
KE Chief Executive Officer | Chief Executive Officer | 2021 – 2024 |
JP Deputy auditor | Deputy auditor | 2022 – 2026 |
MO Audit | Audit | 2022 – 2026 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2022 | |
| Chairperson | 2025 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Former (1) | ||
| Chairperson | 2021 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ATB Antivirals Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kenneth Eugén Sundberg | Chief Executive Officer | 0 companies |
| Juha Pekka Välimäki | Deputy auditor | 0 companies |
| Mika Olavi Leino | Audit | 0 companies |
| Preethy Paul | Chief Executive Officer | 0 companies |
| Reko Pekko Leino | Board of Directors | 0 companies |
| Jaakko Pekka Ollila | Chairperson | 0 companies |
| Lasse Tapani Leino | Chairperson | 0 companies |
| Senthil Kumar Rajendran | Board of Directors | 0 companies |
| John Elias Eriksson | Board of Directors | 0 companies |